2. 2
Forward Looking Statements
This presentation contains certain forward-looking statements. These
statements relate to future events or future performance and reflect
management’s expectations and assumptions regarding growth,
results of operations, performance and business prospects and
opportunities. Such forward-looking statements reflect
management’s current beliefs and are based on information
currently available to management.
A number of factors could cause actual events to differ materially. In
evaluating these statements, prospective purchasers should
specifically consider various risks as more fully outlined in the
prospectus, a copy of which can be obtained online at
www.sedar.com.
2

3. 3
“There’s an epidemic of skin cancer”
- Howard Rogers, Dermatologist, Lead on Medicare research
 Skin cancer strikes 1 in 5 in the U.S.1
 It is the most common form of cancer
 40-50% of Americans who live to 65 expected to get skin cancer 2
 Melanoma kills one person every hour in the US 3
 Melanoma is the #1 cancer killer of women 25-30 4
 Incidence of melanoma rising faster than any other cancer 5
Melanoma is Deadly
Accounts for 75% of
skin cancer deaths6
3

4. 4
Early detection vital to saving lives
100 95% Melanoma Five Year Survival Rate by Tumor Stage 6
80
60
40
20
15%
0
Stage I Stage II Stage III Stage IV

5. 5
Early detection would save billions of dollars
 2 million Americans get skin cancer each year 7 Cost of Treating Melanoma
by Tumor Stage (per patient) 9
 Treating melanoma alone costs $1.5 billion 110.1
($ US thousands)
annually in the U.S. 8 105.5
 Advanced stage melanoma 22 times more
costly to treat than early stage
35.4 38.3
22.5 24.3
11.0 13.7
5.0
Early Stage Late Stage

6. 6
Current skin cancer detection methods limited
 Primary diagnosis done by GPs with varying
Clinical Diagnosis Histological Diagnosis
levels of experience
 Full body examinations seldom conducted
 33.8% sensitivity for melanoma for GPs 10
› Squamous Cell Carcinoma – 41.1%
› Basal Cell Carcinoma – 63.9%
Punch Biopsy
 Biopsies invasive and costly
› Permanent scarring
 ~80% of biopsies test negative 11

7. 7
Breakthrough early stage cancer detection system
Initial Focus: Early detection of skin cancer
 Detects melanoma with 97% accuracy vs. 33.8%
for primary clinical diagnosis
All forms of
Skin Cancer
 Developed by BC Cancer Agency and UBC
 Patented technology
 Exclusively licensed to Verisante Technology, Inc.
Gastrointestinal,
Lung, and Cervical
Cancers

8. 8
Highly automated detection process
Skin cancer: Verisante AuraTM
Near Infrared Raman
Pathology on Spectroscopy
every lesion scanned
Differentiates between
malignant and benign tissue Handheld probe scans
for 21 biomarkers in
an instant
Provides data on chemical
composition of skin based Rapid speed enables
on molecular vibrations full body scans

9. 9
Highly automated detection process
Skin cancer: Verisante AuraTM
Safe, Non-invasive, Fast
Increased survival rates
Reduced treatment costs
No unnecessary biopsies
Reduced waiting times
Real time results
97% accurate for melanoma
91% for other skin cancers

10. 10
Proven in clinical trials by the BC Cancer Agency
Skin cancer: Verisante AuraTM
 6 year clinical study at Vancouver General
Hospital’s Skin Care Center Melanoma
97% sensitivity
 Focused on differentiating cancerous lesions “Percentage identified”
from benign lesions 78% specificity
“Confirmed by biopsy”
 1,000 skin lesions scanned
 Preliminary results published in 2008 based on Cancerous and Precancerous Lesions
274 lesions 12
91% sensitivity
“Percentage identified”
75% specificity
“Confirmed by biopsy”

11. 11
Superior technology over competing systems
Verisante Aura™ Scibase Inc.
• Electrical Impedance Spectroscopy
 Proven technology • 98% sensitivity; specificity < 5%
• Slightly invasive
 Detects all skin cancers • 5 minutes per lesion
• Large probe/expensive disposables
 97% Sensitivity; 78% Specificity Mela Sciences
for melanoma
• Computerized Imaging Technology
• FDA Panel recommends approval by narrow margin
 Measures 21 biomarkers • Key Concern: too many false positives
• 98% sensitivity; 9.5% specificity
 Virtually instant scan • Large probe
Lucid Inc.
 Non-invasive
• Confocal Microscopy
 Tiny Probe • 10-20 min. per lesion
• Dermatologist required
• Large probe
 Inexpensive disposable covers

12. 12
Endoscopic system enables detection of other cancers
Verisante CoreTM
 Clinical studies underway at VGH for early detection of lung & colon cancer
Lung Cancer 13
World’s #1 cancer killer with
1.4 million deaths/year
Colon Cancer
#2 deadliest cancer in U.S.
Cervical Cancer
World’s #2 cause of cancer
deaths among women

13. 13
Strong scientific pedigree
Focused on developing systems for the early detection of cancer
Dr. Branko Palcic
Ph.D.
• Honorary Professor, Dept. of Pathology and Laboratory Medicine, UBC
• Founder, Cancer Imaging and Technology Departments, BC Cancer Agency
• Co-inventor of LIFE-Lung device, used in over 150 major medical centers world-wide
• Friesen-Rygiel Award for Outstanding Canadian Academic Discovery (1999)
• King George V Silver Jubilee Cancer Research Fellow
Dr. Haishan Zeng
Ph.D.
• Senior Scientist, Integrative Oncology Dept. BC Cancer Agency
• Associate Professor, Dermatology and Skin Science, University of British Columbia
• Co-inventor - Verisante™ technology

14. 14
Strong scientific pedigree
Focused on developing systems for the early detection of cancer
Dr. David McLean
MD, FRCPC
• Professor, Dept. of Dermatology and Skin Science, UBC
• President, Cancer Prevention Institute of Canada
• Former President, Canadian Dermatology Association
• Co-inventor - Verisante™ technology
Dr. Harvey Lui
MD, FRCPC
• Professor and Head, Dept. of Dermatology and Skin Science, UBC
• Former Clinical Fellow, Massachusetts General Hospital, Harvard Medical School
• University Killam Prize (2001)
• Co-inventor - Verisante™ technology

15. 15
Clear regulatory pathway to commercialization
Skin cancer: Verisante AuraTM
2010 2011 2012 2013 2014 2015
Production Prototype &
Health Canada Approval Marketing and Sales (Canada)
CE Mark Marketing and Sales (EU, South Africa, Australia)
Clinical Study Clinical Study
Prep. USA
Approval Marketing and Sales (USA)

16. 16
Significant market potential with multiple end users
Skin cancer: Verisante AuraTM
Initial Geographic Markets Staged Rollout Strategy
Recurring revenue from sale of disposable probe shields
STEP 1
Early adopters
~32,000 Dermatologists
Canada
EU
USA
STEP 2
Innovators
South ~950,000 General Practitioners
Africa
STEP 3
Australia Skin Care Clinics
NZ Oncology and Imaging Clinics
HMOs

17. 17
Initial focus on early adopters and innovators
Will drive broader market acceptance
2000
Targeting 14%
penetration by year 5
1600 Dermatologists
United States
1200
Canada, European Union, South Africa,
800
Australia, New Zealand
400
0
Yr. 1 Yr. 2 Yr. 3 Yr. 4 Yr. 5

18. 18
Initial focus on early adopters and innovators
Will drive broader market acceptance
35000
Targeting 6%
30000 penetration by year 5
General Practitioners
25000
United States
20000
15000 Canada, European Union, South Africa,
Australia, New Zealand
10000
5000
0
Yr. 1 Yr. 2 Yr. 3 Yr. 4 Yr. 5

19. 19
Experienced management
Focus: controlling costs, accelerating product development & regulatory approval process
Thomas Braun
BA, JD, LLM – Chief Executive Officer
• Public company experience
• Extensive experience in executing M&As and raising capital
• Advised high tech companies on international business transactions
• Expertise in technology licensing
• Member California Bar Association
Anna Trinh
B.Comm, LLB – Chief Financial Officer and Corporate Counsel
• Experience in counseling companies on regulatory and compliance filings
• M&A and financial transaction experience
• Practiced corporate securities law in private practice

20. 20
Strong, independent Board of Directors
Joe Biegel Chris Dennis
BS, MS (Medical Imaging) MBA
• Vice-President, Product Management & Marketing • Former President, Comcare Health Services
• McKesson Medical Imaging Group • Senior positions with Angiotech
• Senior positions with Agfa Healthcare, Hewlett Pharmaceuticals, Johnson & Johnson / Ortho
Packard, Polaroid Medical Imaging Neutrogena
Karen Boodram Jake Thiessen
BSc, MBA Ph.D.
• Vice-President, Business Development, SemBiosys • Professor Emeritus, University of Toronto
• Former Life Sciences Analyst, PI Financial • Founding Director, School of Pharmacy and
• More than 25 years healthcare experience Health Sciences Campus, University of
Waterloo
• Ten years with Novartis

21. 21
Share Capital
Common Shares 46,188,117
Common Shares (held by Founders) 14,700,000
Total Common Shares Outstanding 60,888,117
Warrants 17,568,600
Incentive Stock Options 3,545,000
Fully Diluted Share Capital 82,001,717

22. 22
Market Comparables
Company Market Capitalization
MELA Sciences, Inc. (NASDAQ: MELA) $93,000,000
Novadaq (TSX: NDQ) $126,000,000
ALI Technologies Inc.
$530,000,000
*Sold to McKesson (NYSE: MCK) in 2002 for $530 Million

23. 23
Summary
 Breakthrough early stage skin cancer detection device
 Patented technology with exclusive worldwide license from BC Cancer Agency
 Clear regulatory pathway to commercialization with significant market potential
 Endoscopic device for early stage detection of lung, colon and cervical cancers in clinical trials
 Strong scientific pedigree and experienced management

24. 24
End Notes
References
1. American Cancer Society. Cancer Facts & Figures 2009
2. National Cancer Institute. Cancer Trends Progress Report 2007, Update April 2008
3. American Cancer Society. Cancer Facts and Figures 2009
4. Melanoma Research Foundation
5. National Cancer Institute. SEER Cancer Statistics Review, 1975-2004
6. National Center for Chronic Disease Prevention and Health Promotion
7. Rogers HW, Weinstock MA, et al. Incidence Estimate of Non Melanoma Skin Cancer in the U.S., 2006, Archives of Dermatology 2010
8. National Cancer Institute. Cancer Trends Progress Report 2007
9. Doru Traian Alexandrescu. Melanoma Costs: A Dynamic Model Comparing Estimated Overall Costs of Various Clinical Stages,
Dermatology Online Journal, Nov 2009
10. Heal CF, Raasch BA, Buettner PG, Weeden D. Accuracy of Clinical Diagnosis of Skin Lesions, British Journal of Dermatology 2009
11. Jones TP, Boiko PE, Piepkorn MW. Skin biopsy indications in primary care practice: a population-based study. JABFP 1996; 9:397–404.
12. Raman Spectroscopy for In Vivo Tissue Analysis and Diagnosis, Instrument Development to Clinical Applications, Journal of
Innovation in Optical Health Sciences 2008
13. Cancer Research UK
14. National Cancer Institute. SEER Database, 1998 – 2000
15. Melamed MR, Flehinger BJ, Zamen MB, et al. Screening for early lung cancer: results of the Memorial Sloan-Kettering study In New
York. Chest 86:44-53, 1984.
16. Cortese DA, Pairolero PC, Bergstralh EJ, et al. Roentgenographically occult lung cancer. A ten-year experience. J Thorac Cardiovasc
Surg 86:373—80, 1983

25. 25
Thank you